Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives
Alain Bitton(McGill University Health Centre), QI consensus group, Wael El‐Matary(Children's Hospital Research Institute of Manitoba), Geoffrey C. Nguyen(Johns Hopkins Medicine), Ellina Lytvyak(University of Alberta), Natasha Kachan(Crohn's and Colitis Canada), Gil Melmed, Maria Vutcovici(McGill University Health Centre), Brian Bressler(University of British Columbia), Jennifer Jones(Dalhousie University), Maida Sewitch(Royal Victoria Regional Health Centre), Péter L. Lakatos(McGill University)
Cited by 43
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k